Chemotherapy Effect, Gastric Cancer
Conditions
Keywords
Circulating exosomal lncRNA-GC1, Advanced Gastric Carcinoma, treatment response
Brief summary
The investigators hope that through the analysis and research to find determine whether lncRNA-GC1 could serve as a non-invasive biomarker for monitoring the neo-adjuvant chemotherapy response for personalized medicine for gastric cancer.
Detailed description
The LncRNA-GC1could noninvasively track dynamics of tumor burden and has been proposed as a real-time biomarker that can provide both predictive and prognostic values. But the value in monitoring the neo-adjuvant chemotherapy response is unclear. The investigators hope that through the analysis and research to find determine whether lncRNA-GC1 could serve as a monitoring biomarker for patients with gastric cancer receiving neo-adjuvant chemotherapy.
Interventions
DIAGNOSTIC_TESTDetection of levels of circulating EV-derived lncRNA-GC1
For patients with gastric cancer receiving neo-adjuvant chemotherapy, the dynamic changes of EV-derived lncRNA-GC1 was detected to identify whether is can serve as a monitoring biomarker for treatment response.
Sponsors
Chinese PLA General Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Having signed informed consent * Age≥ 18 years old * Histologically confirmed gastric adenocarcinoma * radiographically identified as advanced gastric cancer
Exclusion criteria
* Other previous malignancy within 5 year * Surgery (excluding diagnostic biopsy) within 4 weeks prior to study * Pregnancy or lactation period * Legal incapacity
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Detection of levels of circulating exosomal lncRNA-GC1 | Through study completion, an average of 1 year | Levels of circulating exosomal lncRNA-GC1 are detected by RT-PCR |
Countries
China
Outcome results
None listed